Erwin Gäbele

Dr. Erwin Gäbele


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
EGErwin Gäbele
Erwin Gäbele
IGIsabella Gigante
Isabella Gigante
MPMirella Pastore
Mirella Pastore
ACAntonio Cigliano
Antonio Cigliano
Grazia GalleriGrazia Galleri
Grazia Galleri
SSSara Martina Steinmann
Sara Martina Steinmann
Intrahepatic cholangiocarcinoma (iCCA) is the second most common primary liver tumor. Due to its aggressive nature and resistance to conventional treatments, there is a pressing need to develop novel and more effective therapies for this deadly malignancy. Here, we explored the therapeutic potential of the DNA minor groove binders trabectedin (TRB) and lurbinectedin (LUR) for the treatment of iCCA using cell lines, spheroids, cancer-associated fibroblasts (CAFs), patient-derived tumor organoids (PDOs), and the chicken chorioallantoic membrane (CAM) in vivo model. TRB and, more substantially, LUR, significantly inhibited cell growth in iCCA cell lines, spheroids, CAFs, and PDOs at very low nanomolar concentrations. Specifically, the two drugs significantly reduced proliferation, triggered apoptosis, and caused DNA damage in iCCA cells. At the metabolic level, TRB and LUR decreased mitochondrial respiration and glycolysis. At the molecular level, the two compounds effectively downregulated the mammalian target of rapamycin complex 1 (mTORC1) and Hippo/YAP pathways and suppressed the expression of yes-associated protein 1 (YAP1), cellular myelocytomatosis oncogene (c-Myc), E2F transcription factor 1 (E2F1), Bromodomain-containing protein 4 (BRD4), TEA domain transcription factor 4 (TEAD4), and cluster of differentiation 7 (CD7) proto-oncogenes. Furthermore, LUR significantly restrained the in vivo growth of iCCA cells in the CAM model. Our data indicate that TRB and LUR possess strong anti-proliferative and pro-apoptotic activities and could represent promising therapeutic agents for the treatment of iCCA.

21 July 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
EGErwin Gäbele
Erwin Gäbele
IGIsabella Gigante
Isabella Gigante
MPMirella Pastore
Mirella Pastore
ACAntonio Cigliano
Antonio Cigliano
Grazia GalleriGrazia Galleri
Grazia Galleri
SSSara Martina Steinmann
Sara Martina Steinmann
Background and Aims: Intrahepatic cholangiocarcinoma (iCCA) is the second most common type of primary liver tumor. Due to its aggressive nature and resistance to conventional treatments, there is a pressing need to develop novel and more effective therapies for this deadly malignancy. Methods: Here, we explored the therapeutic potential of the DNA minor groove binders Trabectedin (TRB) and Lurbinectedin (LUR) for the treatment of iCCA using cell lines, spheroids, cancer-associated fibroblasts (CAFs), patient-derived tumor organoids (PDOs), and the chicken corioallantoic membrane (CAM) in vivo model. Results: TRB and, more substantially, LUR, significantly inhibited cell growth in iCCA cell lines, spheroids, CAFs, and patient PDOs at very low nanomolar concentrations. Specifically, the two drugs significantly reduced proliferation, triggered apoptosis, and caused DNA damage in iCCA cells. At the metabolic level, TRB and LUR decreased mitochondrial respiration and glycolysis. At the molecular level, the two compounds effectively downregulated the mTORC1 and Hippo/YAP pathways and suppressed the expression of YAP1, c-Myc, E2F1, BRD4, TEAD4, and CD7 proto-oncogenes. Furthermore, LUR significantly restrained the in vivo growth of iCCA cells in the CAM model. Conclusions: Our data indicate that TRB and LUR possess strong antiproliferative and pro-apoptotic activities and could represent promising therapeutic agents for the treatment of iCCA.